The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

The firm's shares rose to $62.17 at the close of Tuesday's trading on news that TPG and Blackstone had offered to take the firm private.

According to the FDA, the tubes are not being produced in conformity with good manufacturing practice and have led to false positive lead test results.

Last week, readers were most interested in a story about an MOU between Gene Solutions and NEWCL to establish a lab in Taiwan.

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds ...

Following an executive reset, the Tokyo firm hopes to grow its molecular and immunochemical testing businesses.

Upfront will use the proceeds to accelerate the commercialization of its lateral flow test, called LVOne, for triaging stroke ...

The firm presented data at AACR that showed the test had high accuracy when distinguishing ovarian cancer at early stages.

During a fireside chat at the RBC Healthcare Conference, Bio-Rad's CFO Roop Lakkaraju confirmed the firm's prior guide for 130 basis points of net tariff impact, which Connor McNamera, RBC's moderator ...

An unnamed party has made a bid to acquire Akoya at a price of $1.40 per share, which Akoya said could prove a superior proposal to its planned merger with Quanterix.